

# Andreas Stahl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6230317/publications.pdf>

Version: 2024-02-01

29  
papers

1,435  
citations

516215

16  
h-index

433756

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ranibizumab in retinopathy of prematurity – one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	18
2	Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity. <i>British Journal of Ophthalmology</i> , 2022, 106, 1573-1580.	2.1	6
3	Artificial Intelligence for Retinopathy of Prematurity. <i>Ophthalmology</i> , 2022, 129, e69-e76.	2.5	23
4	Anti-drug antibodies to brolocizumab and ranibizumab in serum and vitreous of patients with ocular disease. <i>Acta Ophthalmologica</i> , 2022, 100, 903-910.	0.6	8
5	Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial. <i>Ophthalmology Retina</i> , 2022, 6, 628-637.	1.2	16
6	SHIP-MR and Radiology: 12 Years of Whole-Body Magnetic Resonance Imaging in a Single Center. <i>Healthcare (Switzerland)</i> , 2022, 10, 33.	1.0	11
7	Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data. <i>Acta Ophthalmologica</i> , 2021, 99, 201-206.	0.6	5
8	Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy – The non-interventional second year follow-up to the PRIDE study. <i>Acta Ophthalmologica</i> , 2021, , .	0.6	4
9	International Classification of Retinopathy of Prematurity, Third Edition. <i>Ophthalmology</i> , 2021, 128, e51-e68.	2.5	280
10	Individual Risk Prediction for Sight-Threatening Retinopathy of Prematurity Using Birth Characteristics. <i>JAMA Ophthalmology</i> , 2020, 138, 21.	1.4	41
11	Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy – the PRIDE study. <i>Acta Ophthalmologica</i> , 2020, 98, e530.	0.6	19
12	Transcriptional Profiling Uncovers Human Hyalocytes as a Unique Innate Immune Cell Population. <i>Frontiers in Immunology</i> , 2020, 11, 567274.	2.2	27
13	Transcriptomic Characterization of Human Choroidal Neovascular Membranes Identifies Calprotectin as a Novel Biomarker for Patients with Age-Related Macular Degeneration. <i>American Journal of Pathology</i> , 2020, 190, 1632-1642.	1.9	38
14	Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 1551-1559.	6.3	268
15	Acute unilateral maculopathy associated with adult onset of hand, foot and mouth disease: a case report. <i>BMC Ophthalmology</i> , 2019, 19, 104.	0.6	8
16	OCT Angiography of the Choriocapillaris in Central Serous Chorioretinopathy: A Quantitative Subgroup Analysis. <i>Ophthalmology and Therapy</i> , 2019, 8, 75-86.	1.0	40
17	Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials. <i>JAMA Ophthalmology</i> , 2019, 137, 305.	1.4	15
18	Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 13-20.	0.9	101

#	ARTICLE	IF	CITATIONS
19	Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity. JAMA Pediatrics, 2018, 172, 278.	3.3	111
20	Semaphorin 3F Modulates Corneal Lymphangiogenesis and Promotes Corneal Graft Survival. , 2018, 59, 5277.		13
21	Subjective evaluation of visual acuity is not reliable to detect disease activity in different exudative maculopathies. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1565-1571.	1.0	4
22	Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. British Journal of Ophthalmology, 2017, 101, bjophthalmol-2016-308668.	2.1	120
23	Sema3f Protects Against Subretinal Neovascularization In Vivo. EBioMedicine, 2017, 18, 281-287.	2.7	20
24	CNTF Attenuates Vasoproliferative Changes Through Upregulation of SOCS3 in a Mouse-Model of Oxygen-Induced Retinopathy. , 2016, 57, 4017.		17
25	Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 2151-2157.	1.0	53
26	Systemic confounders affecting serum measurements of omega-3 and -6 polyunsaturated fatty acids in patients with retinal disease. BMC Ophthalmology, 2016, 16, 159.	0.6	5
27	The German ROP Registry: data from 90 infants treated for retinopathy of prematurity. Acta Ophthalmologica, 2016, 94, e744-e752.	0.6	31
28	Screening and Treatment in Retinopathy of Prematurity. Deutsches A&#x0308;rzteblatt International, 2015, 112, 730-5.	0.6	12
29	Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1429-1436.	1.0	109